---
title: "Kasvu Therapeutics Raises €30M Series A for TrkB Neuroplastogen"
description: "Kasvu Therapeutics raised a €30 million Series A led by Hadean Ventures to move its TrkB-potentiating drug KTX-0141 through IND/CTA-enabling work and Phase 1/1b development."
date: 2026-09-25T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-kasvu-therapeutics-30m-eur-series-a-hadean
---

# Kasvu Therapeutics Raises €30M Series A for TrkB Neuroplastogen

> Kasvu Therapeutics raised a €30 million Series A led by Hadean Ventures to move its TrkB-potentiating drug KTX-0141 through IND/CTA-enabling work and Phase 1/1b development.

**Kasvu Therapeutics raised a €30 million Series A** on September 24, 2026, led by **Hadean Ventures**.

Tesi and Innovestor Life Science Fund made significant investments. The Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments and Helsinki University Funds also participated.

## Deal terms

| Field | Detail |
| --- | --- |
| Company | [Kasvu Therapeutics](/startup/kasvu-therapeutics) |
| Financing | **€30M Series A** |
| Lead | Hadean Ventures |
| Stage | Preclinical biotechnology |
| Lead program | KTX-0141 |
| Planned use | IND/CTA-enabling studies and Phase 1/1b development |

## A different route to neuroplasticity

Kasvu is developing compounds that potentiate TrkB, a receptor involved in neuroplasticity. Its lead candidate, KTX-0141, is initially being advanced for major depressive disorder, with potential applications in other neuropsychiatric and neurodegenerative conditions.

The company’s differentiation claim is that direct, selective TrkB potentiation could promote neuroplasticity without relying on the psychedelic mechanisms being explored by another group of depression-drug developers. That remains a preclinical thesis. The Series A is designed to produce the toxicology, manufacturing and regulatory package required to begin human testing, then fund Phase 1/1b work.

Kasvu originated from University of Helsinki research, and the investor group combines specialist healthcare capital with Finnish public and university-linked institutions. That syndicate is suited to a program that may require several years of clinical development before commercial evidence emerges.

## What has not been demonstrated

KTX-0141 has not yet established safety or efficacy in humans. Mechanistic differentiation does not guarantee a better therapeutic window, durable clinical benefit or a straightforward regulatory path.

Kasvu did not disclose a valuation, ownership sold or expected runway. Investors should also separate financing milestones from clinical milestones: closing a Series A funds the work but does not de-risk the molecule by itself.

## Bottom line

The transaction is a confirmed **€30 million Series A**. The next decision points are IND/CTA clearance, first-in-human dosing and early safety and pharmacodynamic evidence—not additional preclinical claims.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 25, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.